Astrazeneca Ab

Astra Zeneca U.k. Limited

Astra Pharmaceuticals Limited

Astra Pharmaeuticals Ltd.

David R Cheshire

Martin E Cooper

David K Donald

Mark Furber

Matthew Wd Perry

Richard P Harrison

Nicholas P Tomkinsson

Stephen Connolly

Antonio Mete

Philip Vellacott Thorne

Premji Meghani

Michael Stocks

Jeffrey Paul Stonehouse

Rhona Jane Cox

Roger Victor Bonnert

Francis Ince

David Cladingboel

Simon Hirst

Neal Michael Smith

Cherylin Francis Preston

Matthew W D Perry

John Dixon

Nicholas David Kindon

Roger C Brown

David Cox

Austen Pimm

Bryan Glyn Roberts

Andrew Cooke

Carol Manners

David Hardern

Peter Richard Hamley

Peter A Cage

Ian Millichip

Deborah Chen

Tim Birkinshaw

David Cladinggboel

A compound of formula (I), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders. 

Pyrimidine sulphonamide derivatives as chemokine receptor modulators

A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders. 

There are provided novel compounds of formula (I), wherein R, R, R, T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain 

Arylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase

There are provided novel compounds of formula (I) wherein R, R, R, T, U, X, Y, V and W are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease, CNS disorders and pain.

Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase

The invention provides pharmaceutically useful thieno[2,3-d]pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Treatment of skin disorders using thieno[2,3-D]pyrimidinediones

There is disclosed the use of a compound of formula (I), wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prohylaxis of inflammatory disease

Use of phenylheteroalkylamine derivatives

There are provided novel compounds of formula (I), wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.

Phenylheteroalkylamine derivatives

There is disclosed the use of a compound of formula (I) wherein R, R, X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts, enantiomers or racemates thereof, in the manufacture of a medicament, for the treatment or prophylaxis of diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial. Certain novel compounds of formula (Ia) and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof are disclosed; together with processes for their preparation, compositions containing them and their use in therapy. The compounds of formulae (I) and (Ia) are inhibitors of the enzyme nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease.

Use of phenylheteroakylamine derivatives

There are provided novel compounds of formula (I), wherein R , R , X, Y, V, W and Z are as defined in the specification, and pharmaceutically acceptable salts thereof, and enantiomers and racemates thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of nitric oxide synthase and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain.

The invention provides pharmaceutically useful thieno&lsqb;2,3-d&rsqb;pyrimidinediones, processes for their production, pharmaceutical compositions containing them and methods of treatment involving their use.

Thieno&lsqb;2,3-d&rsqb; pyrimidinediones, their preparation and use in therapy

Thieno&lsqb;2,3-d&rsqb;pyrimidine diones and their use in the treatment of reversible obstructive airways diseases

Pyrrolo&lsqb;3,4-d&rsqb;pyrimidinone derivatives and their use as medicaments

The invention relates to novel pyridyl derivatives, their use as medicaments, pharmaceutical formulations containing them and methods for their preparation.

Pyridine derivatives and pharmaceutical compositions containing them

Growing community of inventors

Loughborough, United Kingdom

David R Cheshire